Venclyxto▼ (venetoclax) film coated tablets: updated recommendations on tumour lysis syndrome (TLS) in CLL patients.

Summary:

• Fatal cases of TLS have been observed even in patients receiving the lowest venetoclax dose used in dose-titration schedule.
• TLS is a known risk of venetoclax.
• Strict adherence to dose titration and TLS risk minimisation measures as outlined in the SmPC is required for all patients.
• A patient card will be provided to prescribing haematologists to be given to each patient.